Another reason we love CBD, there are clinical studies taking place consistently surrounding the benefits, the effects, as medication, and more. Currently, five months into the 2022 calendar year, there are six active clinical trials taking place currently. Six clinical trials may not sound like much, but six studies to learn more about CBD is a step in the right direction in our book.
To learn more about the six clinical trials that are currently taking place, click here. Or, stay tuned and we can keep you updated as the weeks and months go on.
One of the current clinical trials that caught our attention is ” Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota” also known as ClinicalTrials.gov Identifier: NCT05285449
Personally, we think this is another great step for CBD to show and prove just how many benefits it truly has. The focus proposed in this study is to “evaluate the influence of short-term CBD on glucose tolerance and the gut microbiota. Hypothesis: compared with daily ingestion of a placebo, 4-weeks daily ingestion of CBD will improve glucose tolerance and favorably modify the gut microbiota towards a more anti-inflammatory profile” (ClinicalTrials.Gov).
Can you imagine the outcomes and possibilities of this? Coming from a family of diabetes, the struggles, the hurdles, the constant checking levels, cost of insulin, etc. This could be huge. Here’s to being optimistic that CBD can come through and make a difference for those dealing with diabetes.
This study began on February 9, 2022 was first posted on March 17, 2022 and is expected to be completed come March 9, 2023. This is in collaboration with Caliber Foods. There are an estimated 30 participants who will either receive a placebo or active cbd ( 2x 30 mg daily).
The brief summary and detailed description of this study is as follows (ClinicalTrials.Gov). To read more on this study, please click the link above for more detailed information.
While many empirical projects have described multiple potential health benefits of CBD, the potential for CBD to provide protection against the development of diabetes via favorable modification of the gut microbiota has received relatively less attention. We hope to learn if CBD can improve glucose tolerance and the gut microbiota, and if these two improvements might be related.
More than 122 million Americans have diabetes, or its precursor, pre-diabetes. The clinical and public health implications are not trivial as diabetes is the leading cause of blindness and non-traumatic amputation; it is closely associated with vascular disease and premature death, and people with diabetes are at greater risk of serious and fatal complications associated with Covid-19. The defining feature of diabetes is dysfunctional regulation of blood glucose (blood sugar). Although numerous factors contribute to the development of type 2 diabetes, the gut microbiota has recently emerged as an important regulator of glucose homeostasis. Imbalances in the microbiota can lead to intestinal inflammation and loss of gut barrier integrity, which in turn activates inflammatory cascades outside of the gut that can precipitate development of metabolic dysfunction. Changes in the gut microbiota can also alter proportions of microbial metabolites such as secondary bile acids and short chain fatty acids, which have been shown to influence host metabolism. Diet is one of the most important modifiers of the gut microbiota and several plant-based chemicals have been shown to exert beneficial effects on its composition and function. Cannabis sativa L., which produces a suite of phytochemicals, referred to collectively as cannabinoids, has also been shown in epidemiologic studies to exert beneficial effects on glucose regulation. These effects may be, in part, due to interactions with the gut microbiota. The focus of this project is cannabidiol (often abbreviated as CBD). CBD is not marijuana. CBD is not cannabis. CBD is a bioactive phytochemical that is present in the plant Cannabis sativa; it has no psychoactive properties. Over recent years CBD has garnered considerable attention on account of its potential medicinal properties. There is increasing evidence that CBD may have therapeutic and/or preventative effects pertinent to cancer, cardiovascular disease, anxiety, and most relevant to the current proposal, diabetes and the gut microbiota. The aim of the proposed study is to evaluate the influence of short-term CBD on glucose tolerance and the gut microbiota. Hypothesis: compared with daily ingestion of a placebo, 4-weeks daily ingestion of CBD will improve glucose tolerance and favorably modify the gut microbiota towards a more anti-inflammatory profile.
To shop PG Organix CBD products, click here. Please let us know if there is anything we can do to help you!